Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Janssen to start phase III trial of daratumumab in multiple myeloma in Q4 2014 Genmab partner Janssen Biotech (Janssen) is planning to start a new phase III trial of daratumumab for the treatment of patients with multiple myeloma during the fourth quarter of 2014. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Immune Pharmaceuticals begins patient screening for Bertilimumab Phase II clinical trial in Bullous Pemphigoid
Immune Pharmaceuticals has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid.
Contract Research & Services > Clinical Trials > News
Erytech enrolls first patient in Phase II study of ERY-ASP in pancreatic cancer
ERYTECH Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, has announced the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.
Contract Research & Services > Clinical Trials > News

Contract Research

Lightlake Therapeutics gets funding commitment from prominent international R&D foundation
Lightlake Therapeutics, a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, has received a funding commitment from a prominent international research and development foundation.
Contract Research & Services > Contract Research > News
Zealand, Boehringer to advance new peptide medicines
By PBR Staff Writer
Denmark-based Zealand Pharma and Boehringer Ingelheim have entered into a new global exclusive licence, research and development collaboration, which covers a new therapeutic peptide project from Zealand’s portfolio of preclinical programs.
Contract Research & Services > Contract Research > News

Contract Services

Angelini to commercialize Durata's Dalbavancin in certain European Territories, Russia and Turkey
By PBR Staff Writer
Durata Therapeutics International, the Dutch subsidiary of US-based Durata Therapeutics, has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries.
Contract Research & Services > Contract Services > News
Anika Therapeutics, Medline enter commercialization deal for Hyalomatrix
By PBR Staff Writer
US-based Anika Therapeutics has entered into a new agreement with Medline Industries to commercialize the company's advanced wound care product 'Hyalomatrix', in the US on an exclusive basis through 2019.
Contract Research & Services > Contract Services > News